SARS-CoV-2 vaccine and thrombosis: An Expert Consensus on Vaccine-induced Immune
Résumé
Historically, the vaccination strategies developed in the second half of the 20th century have permitted to eradicate infectious diseases. From the onset of COVID-19 pandemic to March 2021, more than 141 million cases and 3 million deaths were documented worldwide with disruption of the economic and social activity, devastating material, physical and psychological consequences. Reports of unusual and severe thrombotic events, including cerebral and splanchnic venous thrombosis and other autoimmune adverse reactions such as immune thrombocytopenia or thrombotic microangiopathies (TMA) in connection with some of the SARS-CoV-2 vaccine have caused a great deal of concern within the population and the medical community. This report is intended to provide practical answers following an overview of our knowledge on these thrombotic events that are extremely rare but have serious consequences. Vaccine hesitancy threatens to reverse the progress made in controlling vaccine-preventable diseases. These adverse events must be put into perspective with an objective analysis of the facts and the issues of the vaccination strategy during this SARS-Cov-2 pandemic. Healthcare professionals remain the most pertinent advisors and influencers regarding vaccination decisions; they have to be supported in order to provide reliable and credible information on vaccines. We need to inform, reassure and support our patients when the prescription is made. Facing these challenges and these observations, a panel of experts express their insights and propose a tracking algorithm for vaccinated patients based on a10-point guideline for decision-making on what to do and not to do.
Domaines
Vaccinologie
Fichier principal
Covid19, vaccine and thrombosis 27 04 21 Rev IE.pdf (1.05 Mo)
Télécharger le fichier
Origine | Fichiers produits par l'(les) auteur(s) |
---|